Arginine Vasopressin Disorder (Diabetes Insipidus)

IWBCA
Feb 13
15 min read

Arginine vasopressin disorders, historically called diabetes insipidus, are rare conditions in which the body produces excessive dilute urine and cannot conserve water appropriately, leading to intense thirst and a high risk of rapid dehydration without prompt recognition and treatment.

Overview

What is arginine vasopressin disorder (diabetes insipidus)?

Arginine vasopressin disorder refers to two closely related conditions in which the body is unable to retain water efficiently, resulting in the kidneys excreting large volumes of very dilute urine. The problem centers on arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), which is normally produced in the hypothalamus, stored in the pituitary, and released into the bloodstream to signal the kidneys to concentrate urine when the body needs to conserve fluid. When AVP is deficient, or when the kidneys do not respond appropriately to it, urine remains dilute even when a person is dehydrated, and thirst becomes intense in an attempt to compensate.

Two main mechanisms account for arginine vasopressin disorders:

Arginine Vasopressin Deficiency (AVP-D): This form occurs when the brain cannot produce or release enough AVP. It is sometimes referred to as central diabetes insipidus. Because AVP is low or absent, the kidneys do not receive a strong signal to conserve water; therefore, urine output remains high unless the hormone is replaced.
Arginine Vasopressin Resistance (AVP-R): This form occurs when AVP is present in normal or high amounts, but the kidneys do not respond to it appropriately. It is sometimes referred to as nephrogenic diabetes insipidus. In this setting, increasing AVP levels alone does not resolve the problem because the kidney’s receptors or downstream signaling pathways are impaired, and specialized treatments are needed to reduce urine volume and maintain fluid balance.

Although these conditions are rare relative to diabetes mellitus, they are important to recognize because untreated AVP deficiency or resistance can lead to rapid dehydration, shifts in sodium levels, and serious complications. With timely diagnosis and individualized therapy, most people can maintain near-normal fluid balance and quality of life.

Symptoms

What are the most common symptoms associated with arginine vasopressin disorders?

Arginine vasopressin deficiency and resistance share a characteristic symptom pattern: excessive production of very dilute urine accompanied by extreme thirst. Without adequate access to fluids or appropriate treatment, dehydration can develop quickly, especially in children, older adults, and people who are acutely ill.

Needing To Urinate Frequently, Including At Night (Nocturia): People with AVP-D or AVP-R often find themselves needing to urinate every hour or two during the day and waking multiple times overnight to empty their bladder. This occurs because the kidneys are unable to concentrate urine, resulting in the production of large volumes of dilute urine around the clock. Sleep becomes fragmented, daytime fatigue worsens, and the need to constantly plan around bathroom access can interfere with work, travel, and daily activities.
Passing Large Amounts of Light-Colored or Clear Urine: In these disorders, the kidneys may produce up to 10 to 20 quarts of urine per day, compared with the typical 1 to 3 quarts in a healthy adult. The urine is usually very pale or almost clear, reflecting low solute concentration. People may notice that each void is unusually large and that urine remains very light even when they feel thirsty, a clue that the kidneys are failing to conserve water when they should.
Extreme Thirst (Polydipsia): Because so much water is lost in the urine, the body’s natural defense is to trigger intense thirst. Individuals with AVP-D or AVP-R may drink large amounts of water or other fluids throughout the day and night and often feel uncomfortable or unwell if they cannot readily access fluids. This thirst is driven by physiology, not habit, and serves as a key warning sign that fluid losses exceed normal regulatory mechanisms.
Risk of Rapid Dehydration When Fluids Are Restricted: If someone with an arginine vasopressin disorder stops drinking, cannot drink due to illness, or does not receive appropriate treatment, dehydration can develop quickly. Signs may include dry mouth, reduced skin turgor, dizziness on standing, a rapid heartbeat, and, in more severe cases, confusion or lethargy. Because the kidneys in AVP-D and AVP-R continue to excrete large amounts of water even when the body is already dry, fluid losses cannot be compensated without active intervention. This makes a timely medical evaluation essential whenever fluid intake falls or symptoms worsen.

These symptoms indicate that fluid balance is not being regulated normally and should never be dismissed as “just drinking a lot of water” or “having a small bladder.” Prompt assessment by a healthcare professional is important to determine whether an arginine vasopressin disorder or another cause of excessive urination and thirst is present.

Childhood Disorders

What symptoms occur in children with arginine vasopressin deficiency or resistance?

Children with AVP disorders can present differently from adults, and early recognition is critical because they have less reserve and can dehydrate more quickly.

Severe Dehydration: Infants and children may develop signs of dehydration, such as sunken eyes, dry mouth, reduced tears when crying, decreased urine output between polyuric episodes, or fewer wet diapers than expected. They may appear listless or unusually sleepy. Because they cannot always express thirst clearly, caregivers must rely on these physical cues, which can progress rapidly if the underlying disorder is unrecognized.
Constipation: Ongoing fluid loss without adequate replacement can leave less water available for the bowel, leading to hard, infrequent stools and discomfort with defecation. In some children, constipation is one of the earliest persistent symptoms when coupled with large urine volumes and thirst.
Vomiting: Vomiting may occur as dehydration and electrolyte disturbances develop, and it can accelerate fluid loss by reducing the child’s ability to keep fluids down. This combination markedly increases the risk of serious imbalance and often prompts emergency evaluation.
Fevers: Unexplained fevers can accompany dehydration or intercurrent illness and may be misattributed to infection alone. When fevers occur alongside very high urine output and increased thirst, an arginine vasopressin disorder should be considered as part of the broader evaluation.
Irritability: Infants and young children may become unusually fussy, difficult to console, or restless when they are thirsty or beginning to dehydrate. Because they cannot always articulate their feelings, irritability is an important behavioral signal that something is wrong.
Growth Faltering (Failure To Thrive): Over time, repeated episodes of dehydration, poor intake, and metabolic stress can impair weight gain and linear growth. Children may fall off their expected growth curves, appear smaller or thinner than peers, or fail to meet growth milestones. In this context, careful assessment of fluid balance and urine output can uncover an underlying AVP-related disorder.

Any child with persistent excessive urination, intense thirst, or signs of dehydration or growth faltering should be evaluated urgently. Early diagnosis and appropriate treatment of arginine vasopressin deficiency or resistance help protect development, support normal growth, and reduce the risk of serious complications.

Causes

What are the most common causes of arginine vasopressin disorders?

The underlying cause of an arginine vasopressin disorder depends on which part of the water-regulation system is affected. Some problems reduce the amount of arginine vasopressin (AVP) that the brain can produce or release. Others prevent the kidneys from responding to AVP even when levels are normal. A third group is specific to pregnancy. Historically, these conditions were grouped under “diabetes insipidus”, but current terminology emphasizes the hormone involved and the mechanism.

Arginine Vasopressin Deficiency (AVP-D)

AVP-D, previously called central diabetes insipidus, develops when the hypothalamus or pituitary gland cannot produce, store, or release enough AVP to signal the kidneys to conserve water. It is the most common form of arginine vasopressin disorder. Specific causes include:

Inherited Gene Variations: Some people are born with changes in genes that control AVP production or the structure of the hormone. These variants can impair normal synthesis, storage, or release of AVP, resulting in a deficiency that typically presents in childhood or young adulthood, often with a family history of similar symptoms.
Damage From Neurosurgery or Head Injury: Surgery near the hypothalamus or pituitary, traumatic brain injury, or bleeding in this region can disrupt the delicate pathways that carry AVP from the brain to the bloodstream. AVP levels may fall immediately after the event or decline over time as scar tissue forms, leading to new-onset excessive urination and thirst.
Inflammatory or Infiltrative Conditions: Diseases such as sarcoidosis, tuberculosis, Langerhans cell histiocytosis, and some autoimmune or granulomatous disorders can infiltrate the hypothalamus or pituitary. This infiltration disrupts hormone-producing tissue and signaling pathways, reducing AVP output and causing AVP-D alongside other pituitary hormone problems.
Tumors In The Hypothalamic–Pituitary Region: Benign or malignant tumors in or near the pituitary stalk and hypothalamus can compress or replace AVP-producing cells. People may present with arginine vasopressin deficiency, visual changes, headaches, or other pituitary hormone deficiencies, depending on the tumor’s size and location.
Idiopathic Cases: In up to half of AVP-D cases, no clear structural, genetic, infectious, or inflammatory cause is identified. These idiopathic cases are still presumed to be autoimmune or inflammatory at a microscopic level, but current diagnostic tools cannot always reveal a specific trigger.

Arginine Vasopressin Resistance (AVP-R)

AVP-R, previously called nephrogenic diabetes insipidus, occurs when the pituitary releases adequate AVP, but the kidneys do not respond appropriately to the signal. In this form, the hormone is present, yet the renal tubules fail to concentrate urine, resulting in large-volume water loss. Specific causes include:

Obstruction Of The Urinary Tract: Long-standing blockage of urine flow, for example, from severe reflux, congenital obstruction, or advanced prostate disease, can damage kidney tubules. Injured tubules become less responsive to AVP, leading to a concentrating defect and high urine output even after the obstruction is relieved.
Inherited Gene Variations Affecting Kidney Response: Some families carry genetic changes in the AVP receptor (V2 receptor) or in aquaporin water channels in the kidney. These variants prevent the kidney from inserting enough water channels into the tubule membrane in response to AVP, so urine remains dilute despite normal or high hormone levels.
Medications That Interfere With AVP Signaling: Certain drugs blunt the kidney’s response to AVP. Examples include long-term use of lithium, some antiviral agents, and older tetracycline derivatives used in high doses. These medications can impair signaling pathways or damage the collecting duct, producing partial or complete resistance to AVP.
Hypercalcemia: Chronically elevated blood calcium levels can injure the kidney tubules and reduce their ability to respond to AVP. Over time, this leads to impaired urine concentration, increased urine volume, and secondary arginine vasopressin resistance, particularly when hypercalcemia is prolonged or severe.
Hypokalemia: Persistently low potassium levels alter kidney cell function and disrupt the mechanisms that concentrate urine. This can reduce the effect of AVP at the tubular level; therefore, individuals with significant hypokalemia may develop a reversible concentrating defect that improves with potassium correction.
Lithium-Related Kidney Injury: Lithium, commonly used to treat bipolar disorder, is a well-known cause of nephrogenic-like AVP resistance. It is taken up by cells in the collecting duct and, over time, can damage the structures needed for AVP to work. This can produce a chronic, sometimes permanent, inability to concentrate urine even if serum AVP is normal or elevated.

Gestational Arginine Vasopressin Disorder (gAVP-D)

Gestational arginine vasopressin disorder is a rare form that occurs only during pregnancy. The placenta produces an enzyme (vasopressinase) that breaks down AVP. In most pregnancies, this enzyme does not cause problems. In some individuals, particularly those with multiple gestations or impaired liver function from conditions such as preeclampsia or HELLP syndrome, vasopressinase activity becomes high enough that AVP is degraded faster than the body can replace it. The result is a functional AVP deficiency with excessive urine output and thirst. Typically, gAVP-D resolves within two to three weeks after the pregnancy ends, once placental hormone production ceases, and vasopressinase levels decline.

Complications

What are the most common complications associated with arginine vasopressin disorders?

The primary complication of arginine vasopressin deficiency (AVP-D) and arginine vasopressin resistance (AVP-R) is clinically significant dehydration, often accompanied by disturbances in sodium and other electrolytes. Because the kidneys continue to excrete large volumes of very dilute urine regardless of the body’s fluid needs, people with these disorders can lose water faster than they can replace it, especially if they are ill, unable to drink, or do not yet have an accurate diagnosis.

In the early stages, many individuals are able to keep up with losses by drinking continuously. They may feel relatively stable as long as water is always available, which can make the condition easy to underestimate. The risk rises sharply when intake drops for any reason: vomiting, surgery, intercurrent illness, limited access to fluids, or simple exhaustion from waking repeatedly at night to drink and urinate. In this setting, dehydration can develop over hours rather than days.

Untreated dehydration from AVP-D or AVP-R can become life-threatening. As fluid losses accumulate, blood pressure may fall, heart rate may rise, and individuals may experience dizziness, severe thirst, dry mouth, nausea, muscle cramps, confusion, or increasing sleepiness. In more advanced cases, seizures or loss of consciousness can occur due to rapid shifts in serum sodium and osmolality. These are medical emergencies. Anyone with an arginine vasopressin disorder who develops symptoms such as marked dizziness, vomiting, extreme fatigue, or an abrupt decline in mental clarity should seek urgent evaluation at the nearest hospital.

Long-term, repeated episodes of dehydration and hypernatremia can stress the kidneys and cardiovascular system and significantly impair quality of life. Effective treatment aims to prevent these cycles by reducing urine output, stabilizing fluid balance, and teaching patients how to respond early to signs of rising risk.

Diagnosis and Testing

How do clinicians diagnose AVP-D or AVP-R?

Because frequent thirst and urination are common symptoms in many conditions, diagnosing AVP-D or AVP-R begins with ruling out more common causes such as uncontrolled diabetes mellitus, diuretic use, high fluid intake without an underlying concentrating defect, and primary polydipsia. A careful history, physical examination, and baseline laboratory tests help determine whether the kidneys are failing to concentrate urine appropriately in the face of rising serum osmolality.

Once an arginine vasopressin disorder is suspected, the diagnostic process has two goals: to confirm that a true concentrating defect is present and to distinguish AVP deficiency from AVP resistance. This distinction is important because it determines whether treatment focuses on replacing AVP, modifying kidney response, or both.

Water Deprivation Test

The water deprivation test is the most reliable formal test for AVP-D and AVP-R. Because it deliberately limits fluid intake in a person who may already be prone to dehydration, it is performed only under close medical supervision, often in a hospital or specialized unit.

During the test, all fluid intake is withheld for a set period while clinicians measure body weight, urine output, urine osmolality, and blood sodium and osmolality at regular intervals. In a person without an AVP disorder, urine volume falls, and urine becomes progressively more concentrated as the body conserves water. In AVP-D or AVP-R, urine remains abundant and very dilute despite rising blood osmolality, confirming a failure of the AVP–kidney axis.

Additional steps, such as administering synthetic AVP (desmopressin) during or after water deprivation, help distinguish AVP-D from AVP-R. A strong concentrating response to desmopressin supports AVP deficiency, whereas little or no response suggests AVP resistance at the kidney level.

Additional tests that help characterize AVP disorders include:

Copeptin Blood Test: Copeptin is a stable peptide fragment released in equal amounts with AVP. Measuring copeptin provides an indirect estimate of AVP secretion. Low copeptin levels in the setting of high serum osmolality support AVP deficiency, whereas normal or high copeptin levels with dilute urine suggest that AVP is being produced but the kidneys are not responding, consistent with AVP resistance.
Blood Glucose Testing: A blood glucose test helps rule out diabetes mellitus as the primary cause of excessive urination and thirst. In diabetes mellitus, high glucose levels drive osmotic diuresis, but urine is not maximally dilute in the same pattern seen in AVP disorders.
Urinalysis and Urine Osmolality: Urinalysis evaluates urine concentration, specific gravity, and the presence of glucose, ketones, or other abnormalities. Measuring urine osmolality quantifies the concentration of solutes in urine. In AVP-D and AVP-R, urine osmolality remains inappropriately low relative to serum osmolality, even when the body is dehydrated, which is a key diagnostic feature.
Imaging of the Hypothalamus and Pituitary: Magnetic resonance imaging (MRI) of the brain, with focal attention to the hypothalamus and pituitary region, can reveal structural causes of AVP deficiency, such as tumors, post-surgical changes, infiltrative disease, or other lesions. A normal MRI does not rule out AVP-D, but abnormal findings can explain the deficiency and guide further treatment.

Taken together, these tests enable clinicians to confirm the presence of an arginine vasopressin disorder, determine whether the primary problem is hormone deficiency or renal resistance, and identify any underlying structural or systemic condition that drives the process. This information is essential for selecting appropriate therapy and for monitoring the risk of complications over time.

Management and Treatment

How are AVP-D and AVP-R (diabetes insipidus) treated?

Treatment depends on the site of the problem in the arginine vasopressin (AVP) pathway: either insufficient hormone production or release (AVP-D) or impaired renal responsiveness to the hormone (AVP-R). In both situations, maintaining access to safe fluids and drinking regularly remains essential, even after medications are initiated, because the underlying tendency to lose water quickly persists.

AVP-D Treatment

Desmopressin is the first-line treatment for arginine vasopressin deficiency (AVP-D). It is a synthetic analogue of AVP that selectively activates the kidney receptors responsible for concentrating urine, with a longer duration of action and fewer effects on blood pressure than natural AVP.

Desmopressin is available in tablet, nasal spray, and injectable formulations. Your healthcare provider tailors the form, dose, and timing to your lifestyle, work schedule, kidney function, and risk of low sodium. The goal is to reduce urine volume and thirst to a manageable level while avoiding over-replacement, which can cause water retention and dangerously low sodium (hyponatremia). Because of this, dose adjustments are often gradual, and you will be given specific instructions about when to take desmopressin, when to skip doses, and how to adapt during illness.

The rare pregnancy-related form, gestational AVP deficiency (gAVP-D), can often be managed with careful fluid intake and, when needed, short-term desmopressin. In many cases, increased drinking is enough because the underlying problem is an excess of placental enzyme that breaks down AVP, which resolves after delivery. When desmopressin is used, doses are chosen cautiously and monitored closely, and symptoms typically improve within days as fluid balance normalizes. The disorder usually fades within two to three weeks after the pregnancy ends.

AVP-R Treatment

Treatment for arginine vasopressin resistance (AVP-R) is more complex because the hormone signal is present, but the kidneys are less responsive. In this setting, simply adding desmopressin does not resolve the problem; the strategy focuses on reducing urine volume and addressing the underlying cause of resistance whenever possible.

Key approaches can include:

Thiazide Diuretics: Paradoxically, low-dose thiazide diuretics can reduce urine output in AVP-R. They work by causing a mild, controlled reduction in blood volume, which leads the kidneys to reabsorb more sodium and water in the proximal tubules. Less fluid then reaches the parts of the kidney that fail to respond to AVP, so the total volume of dilute urine falls. Thiazides must be used with careful monitoring of blood pressure, electrolytes, and kidney function.
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs reduce the production of prostaglandins in the kidney. Prostaglandins normally blunt the action of AVP, so lowering their levels can improve the concentrating response that remains. In AVP-R, this effect can modestly decrease urine volume when NSAIDs are used in a controlled, supervised way. Because NSAIDs can affect kidney function and stomach lining, they are chosen and dosed cautiously, particularly in people with other risk factors.
Addressing Medication-Related Causes: If a current medication is contributing to AVP resistance, such as long-term lithium or certain other drugs, your provider may be able to switch to an alternative that does not interfere with AVP signaling. This change can gradually improve kidney responsiveness and, in some cases, reduce or eliminate the concentrating defect. Any such switch is made by the prescribing team, with due regard for psychiatric or other treatment needs.

In addition, providers may recommend dietary measures such as modest restriction of sodium and total solute intake to reduce the “load” that must be excreted in the urine. As with AVP-D, individuals with AVP-R still require ready access to fluids and clear guidance on fluid intake, particularly during heat, exercise, or illness.

Seeking Care

When should I see my healthcare provider?

If you have AVP-D or AVP-R, regular follow-up is essential. Your healthcare provider will want to:

Monitor symptoms, urine volume, and weight over time
Check blood sodium and other electrolytes to ensure treatment is not causing dangerous imbalances
Review medications and any new health conditions that might affect water balance
Adjust doses of desmopressin, diuretics, or other therapies when your needs change

It can be helpful to bring specific questions to these visits, such as:

Do I have AVP deficiency, AVP resistance, or a gestational form?
What is the most likely cause in my case, and is it reversible or chronic?
Which treatments are recommended now, and what changes might be needed in the future?
How much water should I aim to drink in a typical day, and what should I do on very hot days, during illness, or before surgery?
Are there signs that should prompt an urgent call or emergency evaluation?
Could any of my family members be at increased risk, and if so, should they be evaluated?

Keeping a record of daily fluid intake, urine frequency, and any episodes of dizziness, confusion, or extreme fatigue can make these discussions more precise and help your team fine-tune your plan.

Outlook and Prognosis

What can I expect if I have AVP-D or AVP-R?

For most people, the outlook with AVP-D or AVP-R is good when the condition is recognized and treated. With appropriate medication, structured fluid guidance, and regular monitoring, many individuals live full lives with few restrictions beyond planning for bathroom access and fluids. The primary ongoing task is to prevent dehydration and to avoid large fluctuations in sodium levels.

The risk of serious complications is higher in:

Infants and Young Children: They become dehydrated more quickly and cannot reliably communicate thirst or seek fluids on their own.
Older Adults, Especially Over 65: They may have a reduced sense of thirst, mobility limitations, or other illnesses that make it harder to respond to fluid losses.
People with Certain Mental Health Conditions or Developmental Disabilities: Recognizing symptoms, expressing needs, and independently accessing fluids may be more difficult.

In these groups, extra supervision, clear care plans, and ready access to medical evaluation are especially important. With this support, many of the risks can be reduced significantly.

Additional Common Questions

Why is it no longer called diabetes insipidus?

The terminology was revised to reduce confusion and improve safety. For many years, “diabetes insipidus” and “diabetes mellitus” shared the word “diabetes,” even though they are very different conditions with different causes and treatments. Diabetes mellitus involves high blood sugar and is treated with glucose-lowering strategies. Arginine vasopressin disorders involve disturbances in water balance and are treated by adjusting AVP signaling and fluid intake, rather than by targeting blood glucose.

Because the shared term led to misunderstandings, delays in correct treatment, and occasional medication errors, professional societies recommended renaming diabetes insipidus as:

Arginine Vasopressin Deficiency (AVP-D) for what was called central diabetes insipidus
Arginine Vasopressin Resistance (AVP-R) for what was called nephrogenic diabetes insipidus

These names identify the specific hormone and mechanism involved, clarifying that AVP-D and AVP-R are disorders of water regulation. The historical term “diabetes” itself comes from a Greek word meaning “to pass through,” reflecting excessive urine flow that is shared by both diabetes mellitus and arginine vasopressin disorders. The updated terminology preserves that history while prioritizing safer, more precise communication in contemporary care.

The IWBCA provides the information and materials on this site for educational and informational purposes only. The content is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult your physician or another qualified healthcare provider regarding any questions you may have about a medical condition, diagnosis, or course of treatment. Do not disregard, delay, or alter medical advice based on information obtained from this site. If you believe you are experiencing a medical emergency, call 911 or your local emergency services immediately.